BoxLife recaps the ranking: retatrutide gets B, BPC-157 low C, NAD+ D and epitalon F. Exercise is the only thing Nippard puts in S tier.
Recap by typeshit. Full story at BoxLife Magazine.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short post says people losing weight on drugs like Ozempic should keep an eye on common nutrient gaps, and links out to a longer list.
Medscape reports national data showing the January 2026 pill launch picked up faster early than injectable tirzepatide or semaglutide did.
Loading…